Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis
PLOS ONE · 07.06.2024 · 19 (6) · e0304241
DOI: 10.1371/journal.pone.0304241 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 07.06.2024. Verfasst von Sarah Sewaralthahab und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fertility, Hydroxyurea. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Plan for Science, Technology and Innovation.
Abstract (Originalsprache)
Background
Evidence supports the benefits of hydroxyurea (HU) in adults with sickle cell disease (SCD), but reservations remain due to long-term concerns of fertility. Retrospective analysis of clinical records of SCD patients (haemoglobin SS genotype) have identified gender-related differences in disease progression. This could inform risk stratification during SCD at diagnosis with the possibility to guide therapeutic decisions.
Methods
This systemic review and meta-analysis evaluated fertility parameters in both children (aged ≥ 6 years) and adults with SCD receiving HU therapy. Studies were sourced from PubMed and EMBASE from inception to July 2023. A total of 160 potentially relevant articles were identified.
Results
Four studies were included that evaluated the effects of HU on sperm parameters in males. A further 4 studies assessed anti-mullerian hormone (AMH) levels and ovarian reserves in females. Differences from baseline values were used to identify compromised fertility. Amongst males, HU treatment negatively impacted the concentration of spermatozoa (MD = -15.48 million/mL; 95% CI: [-20.69, -10.26]; p< 0.001), which continued following treatment cessation (MD = -20.09 million/mL; 95% CI: [-38.78, -1.40]; P = 0.04). HU treatment also led to lower total sperm counts (MD = -105.87 million; 95% CI: [-140.61, -71.13]; P< 0.001) which persisted after treatment (MD = -53.05 million; 95% CI: [-104.96, -1.14]; P = 0.05). Sperm volume, initial forward motility and morphology were unaffected by HU treatment. In females, HU treatment decreased the mean AMH levels 1.83 (95% CI [1.42, 2.56]. A total of 18.2.% patients treated with HU showed reduced ovarian reserves. Interpretation & conclusions This systemic review and meta-analysis suggest that the use of HU for SCD impacts seminal fluid parameters in males and can diminish AMH levels and ovarian reserves in females.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia.
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
- Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Abdulrahman Alsultan
Förderung
- National Plan for Science, Technology and Innovation
Zitieren
APA
Sewaralthahab, S., Alsubki, L. A., Alhrabi, M. S., & Alsultan, A. (2024). Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis. PLOS ONE, 19(6), e0304241. https://doi.org/10.1371/journal.pone.0304241
Vancouver
Sewaralthahab S, Alsubki LA, Alhrabi MS, Alsultan A. Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis. PLOS ONE. 2024;19(6):e0304241. doi:10.1371/journal.pone.0304241
BibTeX
@article{Sewaralthahab2024,
author = {Sewaralthahab, Sarah and Alsubki, Lujain A and Alhrabi, Maram S and Alsultan, Abdulrahman},
title = {Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0304241},
doi = {10.1371/journal.pone.0304241}
}
EUVIMED